Next Science (ASX:NXS) EBITDA Margin % : -54.85% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Next Science's EBITDA for the six months ended in Dec. 2023 was A$-9.89 Mil. Next Science's Revenue for the six months ended in Dec. 2023 was A$18.03 Mil. Therefore, Next Science's EBITDA margin for the quarter that ended in Dec. 2023 was -54.85%.

Next Science EBITDA Margin % Historical Data

The historical data trend for Next Science's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science EBITDA Margin % Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-287.72

-343.76

-107.38

-108.38

-65.02

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial					-113.42	-115.13	-102.58	-77.16	-54.85

Competitive Comparison of Next Science's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Next Science's EBITDA Margin % falls into.

Next Science EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Next Science's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.546	/	33.135
	=	-65.02 %

Next Science's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-9.889	/	18.028
	=	-54.85 %

Next Science (ASX:NXS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Next Science EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Next Science's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines